The discovery of galm deficiency (Type iv galactosemia) and newborn screening system for galactosemia in japan

17Citations
Citations of this article
38Readers
Mendeley users who have this article in their library.

Abstract

The Leloir pathway, which consists of highly conserved enzymes, metabolizes galactose. Deficits in three enzymes in this pathway, namely galactose-1-phosphate uridylyltransferase (GALT), galactokinase (GALK1), and UDP-galactose-4′-epimerase (GALE), are associated with genetic galactosemia. We recently identified patients with galactosemia and biallelic variants in GALM, encoding galactose epimerase (GALM), an enzyme that is directly upstream of GALK1. GALM deficiency was subsequently designated as type IV galactosemia. Currently, all the published patients with biallelic GALM variants were found through newborn screening in Japan. Here, we review GALM deficiency and describe how we discovered this relatively mild but not rare disease through the newborn screening system in Japan.

Cite

CITATION STYLE

APA

Kikuchi, A., Wada, Y., Ohura, T., & Kure, S. (2021, December 1). The discovery of galm deficiency (Type iv galactosemia) and newborn screening system for galactosemia in japan. International Journal of Neonatal Screening. MDPI. https://doi.org/10.3390/ijns7040068

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free